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paroxetine (expected cost = $688 for 76 SFDs), for an incre-
mental cost effectiveness ratio of $2.79/SFD ($1004/Symptom-
free year). Paroxetine was dominated under the SOC perspective.
Total expected cost from the SOC perspective was $3676 and
$3529 for paroxetine and escitalopram, respectively. Sensitivity
analysis was conducted on upper and lower efﬁcacy boundaries,
yielding similar incremental cost-effectiveness results. CON-
CLUSION: Escitalopram is cost-saving in the treatment of GAD
under the SOC perspective in Canada, and appears to be cost-
effective under the MoH perspective.
PMH2
of ADHD (Hyperkinetic Disorder: ICD-10 F90.0, F90.1).
METHODS: Using the comprehensive claims database of the
ofﬁcial physicians’ organization of Nordbaden (KVNB, with an
insured population of 2.234m in 2003), n = 630 ADHD patients
age 20 and beyond were identiﬁed. The ADHD group was
matched with a non-ADHD cohort (n = 630) on a 1 :1 ratio
based on age and gender, and the rate of co-existent conditions
was compared between both groups. Chi-square statistics was
used to explore levels of signiﬁcance. RESULTS: The most preva-
lent psychiatric conditions associated with ADHD in adults
included depressive episodes (F32: prevalence 30.3%; relative
risk [RR] 7.1*** [p < 0.001]), recurrent depressive disorder
(F33: 14.3%, RR 12.9***), persistent mood disorders (F34:
7.0%, RR 11.0***), anxiety disorders (F41: 15.7%, RR
5.8***), adjustment disorders (F43: 18.9%; RR 6.6***), other
neurotic disorders (F48: 8.6%, RR 6.8***), speciﬁc personality
disorders (F60: 14.1%; RR 22.3***), other behavioral/emo-
tional disorders with onset in childhood/adolescence (F98: 9.0%;
RR 57.0***), mental/behavioral disorders due to substance use
(F19: 4.9%; RR 7.8***) or due to use of alcohol (F10: 4.6%;
RR 5.8***), and eating disorders (F50: 4.3%, RR 13.5***).
Non-psychiatric conditions associated with ADHD included
obesity, metabolic, infectious and allergic disorders, including
asthma bronchiale, and diseases of the ear and hearing loss but
not disorders of the eye and visual disturbances. Detailed analy-
ses by age and gender will be presented. CONCLUSIONS: These
data point to signiﬁcant comorbidity associated with ADHD in
grown-ups, thus underscoring the clinical relevance of the con-
dition. They provide a basis for further epidemiological research
and for analyses of the cost associated with ADHD in adult
patients.
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With reported prevalence rates of 2–10%, ADHD is one of the
most common disorders of childhood and adolescence. Only
recently, comorbidity has been recognized as one of the most
important aspects of the disorder. OBJECTIVES: To determine
real-world prevalence rates for psychiatric and non-psychiatric
comorbid conditions in children and adolescents with a diagno-
sis of ADHD according to ICD-10 criteria (Hyperkinetic
[Conduct] Disorder, HKD/HKCD, F90.0/F90.1), using the
Nordbaden claims database covering 2.238m insured persons in
South-Western Germany (82% of the regional population).
METHODS: A total of n = 11,245 ADHD patients age 19 or
less were identiﬁed. The ADHD group was matched with a non-
ADHD cohort (n = 11,228) on a 1 :1 ratio based on age and
gender, and the rate of co-existent conditions was compared
between both groups. Chi-square statistics was used to explore
levels of signiﬁcance. RESULTS: The most frequent psychiatric
comorbidities (in 20–40% of patients, each; all p < 0.001; rela-
tive risks compared to control cohort 3–8) included mood and
affective disorders, conduct disorders, speciﬁc developmental
disorders, including those of scholastic skills. Signiﬁcant associ-
ations (similar magnitude) were also found for ADHD and
adjustment disorders, habit and impulse disorders, tic disorders,
sleep disorders, disorders associated with sexual development,
maltreatment syndromes, mental retardation, lack of expected
normal physiological development and disorders due to brain
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ADHD in children and adolescents is associated with substantial
comorbidity. Longitudinal studies have shown ADHD to fre-
quently persist into adulthood. OBJECTIVES: To use adminis-
trative data from Nordbaden / Germany to assess the extent of
co-existing medical conditions in grown-ups with a diagnosis 
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damage—though these occurred less commonly (<10% of
patients each). The analyses also revealed signiﬁcantly increased
relative risk (25–100%) for non-psychiatric disorders involving
immune mechanisms, neurological disorders, metabolic disor-
ders, diseases of the skin and ear, pulmonary and upper respira-
tory diseases, certain gastrointestinal disorders, diseases of the
blood and blood-forming organs, and accidents and injuries (all
p < 0.001). Detailed ﬁndings by age and gender will be presented.
CONCLUSIONS: These data indicate substantial comorbidity
associated with ADHD in children and adolescents. They
provide a basis for further epidemiological research and for
analyses of the cost associated with ADHD.
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OBJECTIVE: To estimate the cost-effectiveness of atomo-
xetine for the treatment of children and adolescents with 
Attention Deﬁcit/Hyperactivity Disorder (ADHD) in Norway.
METHODS: A modeled economic evaluation calculated the
incremental cost per quality-adjusted life years (QALYs) gained
of atomoxetine compared to two stimulant therapies and “no
medication”. Treatment algorithms with and without atomoxe-
tine were compared in patient subgroups stratiﬁed by prior treat-
ment history and whether stimulant medication was appropriate.
A Markov process incorporated fourteen health states repre-
senting hypothetical treatment outcomes for which utility values
were sought from parents of patients through survey. Aspects of
effectiveness and safety of each medication were based on a
review of controlled clinical trials and other clinical literature.
Monte-Carlo simulation was run over a one-year duration from
the perspective of the Norwegian health care system. RESULTS:
In stimulant-naive patients, the incremental cost per QALY of
atomoxetine was NOK 199,178 and NOK 149,892 when com-
pared to immediate-release (IR) and extended-release (XR)
methylphenidate, respectively. In stimulant-failed patients, the
incremental cost-effectiveness of atomoxetine was NOK 168,154
per QALY gained. The incremental cost per QALY of atomoxe-
tine compared to no medication in patients contra-indicated for
stimulants was NOK 175,105. Sensitivity analysis showed that
the utility values for each treatment were important determinants
of the cost-effectiveness of atomoxetine. CONCLUSIONS:
Results of the modeled economic evaluation suggest atomoxe-
tine offers a value-for-money alternative in the treatment of 
children with ADHD in Norway.
PMH6
TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY
DISORDER (ADHD): ARE U.S. COST-EFFECTIVENESS
FINDINGS BASED UPON THE MTA STUDY RELEVANT TO
MENTAL HEALTH CARE POLICY MAKERS IN GERMANY?
Schlander M1, Schwarz O1,Trott GE1,Taylor E2, Jensen PS3,
Garcia JA3, Glied S3, Crowe M3
1Institute for Innovation & Valuation in Health Care (InnoVal-HC),
Eschborn, Germany; 2King’s College, London, UK; 3Columbia
University, New York, NY, USA
The U.S. MTA Study represents the most important randomized
trial of ADHD treatment strategies that has undergone economic
evaluation. Yet there are distinct differences between the United
States and Germany regarding diagnostic criteria, treatment pref-
erences, health care utilization patterns, and unit costs related to
ADHD. OBJECTIVE: To evaluate, based on the MTA, the cost-
effectiveness of clinically proven treatment strategies for ADHD
from the perspective of the statutory health insurance (SHI) in
Germany, and to provide cost-utility estimates. METHODS: A
total of 579 children with ADHD, combined type (DSM-IV),
aged 7–10, were assigned to 14 months of routine community
care (CC), medication management (MedMgt), intensive behav-
ioral treatment (Beh), or the two combined (Comb). Diagnostic
data were used to identify patients meeting the stricter ICD-10
criteria for Hyperkinetic (Conduct) Disorder (HKD, F90.0, or
HKCD, F90.1; n = 145). Clinical effectiveness was determined
using ADHD symptom normalization rates, and utility estimates
came from the literature. Costs were calculated for resources
used, excluding the research component of the study, using
current (2005) SHI acquisition costs. Time horizon of the analy-
sis was one year. RESULTS: MedMgt, compared to CC, led 
to an incremental cost per patient normalized of €2088 (or
€17,850-32,630/QALY), dominating the Beh strategy. Comb,
compared to MedMgt, was associated with an ICER of €55,441
Euro per patient normalized. Deterministic and stochastic sensi-
tivity analyses (by nonparametric bootstrapping) demonstrated
the robustness of these ﬁndings over a broad range of assump-
tions, including less costly routine care. CONCLUSIONS:
Despite substantial differences in ADHD diagnosis and treat-
ment between the U.S. and Germany, these results for Germany
concur with overall U.S. ﬁndings in clearly showing dominance
of MedMgt compared to Beh for HKD/HKCD. Based upon the
MTA, adding intensive Beh to MedMgt (“Comb”) in patients
with HKD/HKCD is associated with an estimated cost per QALY
gained in the range of €474,000–866,000.
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OBJECTIVES: To measure the social and economic burden of
ADHD in the perspective of families, NHS and Italian society.
METHODS: Cost of illness and quality of life analysis based on
an observational case-control, parallel groups, retrospective data
collection on the use of medical resources and social services over
12 months. The study underwent EC approval and informed
consent was obtained. Consecutive patients of age 5 to 18 years,
were recruited at 4 neuro-psychiatry clinics, and allocated to 
4 groups: K (controls) including subjects with mild anxiety/
depression (C-GAS < 50); A, subjects with recently diagnosed
ADHD; B, ADHD managed by psycho-educational interven-
tions; C ADHD managed by pharmacological treatment+psyco-
educational interventions. Resource utilisation was measured
with a structured questionnaire administered to parents and QoL
with the CHIP-CE, Parent Form. RESULTS: (Only ADHD data
vs. controls are presented) 244 subjects were enrolled: K = 69
age = 12.2yrs (SD + 3.3), ADHD = 175 age = 10.9 (SD + 2.6).
ADHD patients were mostly male children, living in large, well-
off families showing higher probability vs. controls of needing
hospital admissions (OR = 3.0; 95%IC 1.4–6.3, p = 0.005), psy-
chologist consultations (OR = 4.9; 95%IC 2.2–10.9, p < 0.001),
lab tests (OR = 2.6; 95%IC 1.4–4.7, p = 0.005) and ECG (OR
= 2.2; 95%IC 1.2–4.2, p = 0.011). ADHD patients also showed
